Implanet Q1 revenue dips 9%, US spinal sales up 16%: 5 things to know

Laura Dyrda -   Print  |

Implanet reported first quarter revenue dropped 9 percent over the same time last year.

Here are five key notes.

1. Total revenue decreased 9 percent to nearly $2.5 million.

2. Spine revenue dropped 2 percent to around $1.3 million while the knee and arthroscopy revenue dropped 17 percent to $1.1 million

3. In France, Jazz spinal implant sales were down 5 percent compared to the same period last year. However, in the U.S., Jazz sales were up 16 percent.

4. In the first quarter, Implanet sold 2,018 Jazz units, flat from the first quarter of 2017.

5. During the quarter, Implanet set up its direct sales force in several European companies to strengthen local surgeon support. "In the current environment, we are confident in our growth prospects for 2018 and beyond," said CEO Ludovic Lastennet.

More articles on orthopedic devices:
DePuy Synthes, Stryker, SpineGuard & more: 8 device company notes
How will proposed Trump, China tariffs affect medtech and healthcare? 5 key thoughts
15 spine devices receive FDA 510(k) clearance in March 2018

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers